Retatrutide is the next-generation weight loss peptide from Eli Lilly that hits three receptors at once: GLP-1, GIP, and glucagon. In phase 2 trials, retatrutide produced 24% body weight loss at 48 weeks at the highest dose, the largest weight reduction ever recorded in a non-surgical obesity drug. This guide explains how retatrutide works, the trial data, expected results vs semaglutide and tirzepatide, dosing protocols, side effects, and what to know before considering it for research use.
Retatrutide is not yet FDA-approved (approval expected late 2026 or 2027), but research-grade material is available for laboratory study. Customer reports we have seen in 2026 align with the trial data: 1.5 to 2.5 kg per week loss in early weeks, plateau around month 4, with dose-dependent gastrointestinal side effects.
What Is Retatrutide?
Retatrutide is a triple agonist peptide that activates three different receptors involved in metabolic regulation:
- GLP-1 receptor: like semaglutide. Slows gastric emptying, increases satiety, improves insulin response.
- GIP receptor: like tirzepatide. Enhances insulin sensitivity and complements GLP-1’s appetite effects.
- Glucagon receptor: unique to retatrutide. Increases energy expenditure and lipolysis, the fat-burning side. This is what produces the larger weight loss compared to semaglutide and tirzepatide.
The molecular structure is a 39-amino-acid peptide with a fatty acid chain that extends half-life to about 6 days, allowing weekly dosing.
The Phase 2 Trial: 24% Body Weight Loss
The pivotal phase 2 study (Jastreboff et al., NEJM 2023) randomized 338 adults with obesity to placebo, 1 mg, 4 mg, 8 mg, or 12 mg weekly retatrutide for 48 weeks. Mean weight loss results:
| Dose | Mean weight loss at 48 weeks | % with 15%+ loss | % with 25%+ loss |
|---|---|---|---|
| Placebo | -2.1% | 2% | 0% |
| 1 mg | -8.7% | 27% | 3% |
| 4 mg | -17.1% | 62% | 26% |
| 8 mg | -22.8% | 83% | 48% |
| 12 mg | -24.2% | 83% | 48% |
For context, semaglutide (Wegovy) at 2.4 mg weekly produces about 15% loss over 68 weeks. Tirzepatide (Zepbound) at 15 mg weekly produces about 22.5% loss over 72 weeks. Retatrutide produced 24% loss in 48 weeks at the high dose, faster than either competitor.
Critically, the weight loss curve had not plateaued at week 48. Trial extensions are evaluating whether the trajectory continues toward 30%+ loss with longer use.
How Retatrutide Compares to Semaglutide and Tirzepatide
| Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1, GIP | GLP-1, GIP, Glucagon |
| Max weight loss | ~15% | ~22% | ~24% (likely higher) |
| Time to plateau | ~14 months | ~16 months | >12 months (TBD) |
| Dosing | Weekly | Weekly | Weekly |
| FDA status | Approved | Approved | Phase 3 ongoing |
| Cost (research grade) | $$ | $$$ | $$$$ |
Retatrutide’s advantage is the additional energy expenditure component (glucagon agonism). This means weight loss happens not just through eating less but through burning more, a mechanism semaglutide and tirzepatide do not have. The downside: more side effect potential and higher cost.
For a deeper comparison see our three-way GLP-1 comparison.
Retatrutide Dosing Protocol
Most research-use protocols mirror the trial titration:
- Weeks 1 to 4: 2 mg weekly
- Weeks 5 to 8: 4 mg weekly
- Weeks 9 to 12: 6 to 8 mg weekly
- Weeks 13+: 8 to 12 mg weekly (only if tolerated)
The slow titration is critical. Jumping to 8 mg without dose-escalation produces severe nausea and vomiting that drives most users to stop. The trial used a similar 4-week-per-step ramp.
Injection: subcutaneous, abdomen or thigh, once weekly. Same day each week to maintain consistent plasma levels.
Reconstitution
Research-grade retatrutide ships as lyophilized 10 mg vials. Standard reconstitution:
- Add 1 mL bacteriostatic water to a 10 mg vial → 10 mg/mL
- 2 mg dose = 0.2 mL (20 units on insulin syringe)
- 4 mg dose = 0.4 mL (40 units)
- 8 mg dose = 0.8 mL (80 units)
Refrigerate after reconstitution; stable 30 days. See our reconstitution guide for full technique.
Side Effects of Retatrutide
Side effect profile from the phase 2 trial:
- Nausea: 35 to 60% of users at higher doses, especially during titration
- Diarrhea: 21 to 27%
- Vomiting: 16 to 22%
- Constipation: 11 to 17%
- Heart rate increase: 4 to 9 bpm at rest (the glucagon effect)
- Mild blood pressure elevation: typically 2 to 4 mmHg systolic
The cardiovascular signals (elevated HR and BP) are unique to retatrutide compared to semaglutide and tirzepatide. They are dose-dependent and reverse on discontinuation. Phase 3 trials are evaluating long-term significance.
What was NOT seen in the trial: significant pancreatitis, thyroid C-cell tumors, gallbladder events at rates above placebo. The class warnings from semaglutide may or may not transfer.
Who Should Consider Retatrutide
The use case is specific:
- Failed semaglutide or tirzepatide: inadequate weight loss or plateau on the existing GLP-1 class.
- Significant obesity: BMI 35+ where the additional 5 to 10% loss matters clinically.
- Tolerant of GI side effects: retatrutide has a higher GI side effect rate than semaglutide.
- Available cash flow: research-grade retatrutide is more expensive than semaglutide due to lower production scale.
Retatrutide is probably overkill for users who have not yet tried semaglutide or tirzepatide and have moderate weight loss goals. Start with the older drugs first.
Common Retatrutide Mistakes
- Skipping the titration ramp: jumping straight to 8 mg causes severe nausea. Always escalate over 4-week steps.
- Not adjusting for cardiovascular effects: monitor heart rate and BP. If sustained tachycardia or BP elevation, drop dose or stop.
- Inadequate protein intake: rapid weight loss without protein discipline accelerates lean mass loss. Target 1.6 to 2.0 g/kg.
- Using tirzepatide protocols: retatrutide is more potent. The same mg dose produces more effect, and skipping that adjustment causes preventable side effects.
- Stopping too early: weeks 1 to 4 are mostly side effects with limited weight loss. The fat loss accelerates from week 8 onward.
Frequently Asked Questions
When will retatrutide be FDA approved?
Phase 3 trials began in 2023. Eli Lilly expects FDA submission in 2025 to 2026 with potential approval in late 2026 or 2027. Until approved, retatrutide is research-use only and not available through standard pharmacies.
Is retatrutide better than tirzepatide?
For raw weight loss, yes. Retatrutide produced 24% loss vs tirzepatide’s ~22% in head-to-head equivalent durations. The trade-offs are higher cost, more GI side effects, and modest cardiovascular signals (elevated heart rate and BP). For users tolerating tirzepatide well, switching may not be worth it.
Can I switch from semaglutide or tirzepatide to retatrutide?
Yes, after a 1 to 2 week washout. Start retatrutide at 2 mg weekly even if you were on a higher tirzepatide dose; the receptor activation differs and titration is still required. Most users who plateau on tirzepatide and switch to retatrutide see additional weight loss within 4 to 8 weeks.
How long until I see results?
Appetite reduction is noticeable in week 1 to 2. Visible weight loss begins by week 3 to 4. Significant loss accumulates from week 8 onward. The 24% benchmark from the trial took 48 weeks; expect 12 to 18 months of consistent use for maximum effect.
Do I need to cycle off retatrutide?
Unlike performance peptides, GLP-1 class drugs are designed for continuous use. Most users continue indefinitely or until target weight is reached, then taper. Stopping abruptly often produces 50 to 70% weight regain within 12 months, similar to semaglutide and tirzepatide.
Where can I get research-grade retatrutide?
For research-grade retatrutide in Indonesia and Southeast Asia, see our pricelist. Order directly via WhatsApp with temperature-controlled delivery.
Related Guides
This article is for informational and research-use purposes only. Retatrutide is not yet FDA-approved for human therapeutic use. Always consult a qualified medical professional before starting any new protocol.